Pardes Biosciences, Inc. (PRDS) News
Filter PRDS News Items
PRDS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
PRDS News Highlights
- PRDS's 30 day story count now stands at 3.
- Over the past 14 days, the trend for PRDS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PRDS are CVR.
Latest PRDS News From Around the Web
Below are the latest news stories about PARDES BIOSCIENCES INC that investors may wish to consider to help them evaluate PRDS as an investment opportunity.
Pardes Biosciences Announces Closing of Tender OfferCARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent |
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesLARKSPUR, Calif., August 28, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the "CVR") associa |
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesLARKSPUR, Calif., August 17, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more |
Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsCARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing, plus a non-tradeable contingent value right (the CVR) associated wi |
Pardes Biosciences Reports First Quarter 2023 Financial ResultsCARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize shareholder value that may potentially result in changes to our business strategy,” said Thomas G. Wiggans, Chief Executive Officer and Chair of Pardes Biosciences. First Quarter 2023 Financial Results Pard |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with the biggest pre-market stock movers that traders will want to keep an eye on for Monday morning! |
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors for progression to severe disease experienced rapid clearance of SARS-CoV-2 virus and evidence of rapid alleviation of targeted and key COVID-19 symptoms independent of treatment arm Based on these results, Pardes to suspend further clinical developme |
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateData from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for the next twelve months CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing pomotrelvir as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment of COVID-19, today reported financial results for |
Pardes Biosciences to Present at SVB Securities Global Biopharma ConferenceCARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET. A live audio webcast of the fireside chat wil |
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdatePhase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, today reported financial results for the third quarter ended September 30, 2022 and provided a business |